Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Janneke Horn et al.|The Lancet Rheumatology|2020Cited by 199
Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patientsRutger Koning, Esther J. Nossent, Paul Bastard et al.|Intensive Care Medicine|2021Cited by 132
Neurofilament light increases over time in severe COVID-19 and is associated with deliriumPatrick Smeele, Niels van Mourik, Lisa Vermunt et al.|Brain Communications|2022Cited by 19
Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trialEndry H. T. Lim, Rutger Koning, Alexander P. J. Vlaar et al.|Respiratory Research|2022Cited by 18
Endothelial Permeability and the Angiopoietin/Tie2 System Following Mild and Severe COVID-19Carolien Volleman, Niels van Mourik, Roselique Ibelings et al.|Artery Research|2023Cited by 4